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Immunodominant epitopes of a3(IV)NC1 induce autoimmune
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Immunodominant epitopes of a3(IV)NC1 induce autoimmune
glomerulonephritis in rats.
Background. The major Goodpasture antibody binding epi-
topes have been localized to the amino-terminal third of the
noncollagenous domain (NC1) of the a3 chain of type IV col-
lagen [a3(IV)NC1]. The present study determined whether the
same epitopes induce glomerulonephritis in rats.
Methods. We immunized Wistar Kyoto (WKY) rats with hu-
man a3(IV)/a1(IV)NC1 chimeric proteins or full-length recom-
binant a3(IV)NC1 (a3732). Chimeric protein constructs were
thirds of a3(IV)NC1 (CP333) replaced by corresponding se-
quences of homologous nonreactive a1(IV)NC1 (CP111). All
chimeric proteins contained 30 amino acids of type X collagen
at the amino terminus except a3732. Two other constructs, T195
EA (EA) and T194 EB (EB), were entirely a1(IV)NC1, except
for antibody-immunodominant amino acids from the first and
second thirds of a3(IV)NC1.
Results. Construct immunized animals developed specific an-
tibody responses to recombinant proteins and native human,
bovine and rat NC1. CP311 immunized rats, as well as a3732
rats, had glomerular IgG, fibrin, and glomerulonephritis with
proteinuria by 3 weeks. CP331 produced more severe disease,
comparable to positive controls. CP111 produced no disease.
EA, but not EB, induced severe glomerulonephritis. Half-dose
each of EA plus EB induced disease identical to full-dose EA
alone.
Conclusion. The amino third of a3(IV)NC1 which contains
the major epitope for Goodpasture antibody binding, also
induces glomerulonephritis in rats. The middle third of
a3(IV)NC1 does not induce glomerulonephritis but appears
to enhance disease with the amino terminal third. Finally, the
presence of the collagen X leader sequence appears to convey
greater nephritogenicity. These studies suggest that not only the
nephritogenic epitope itself, but flanking sequences and the con-
formational context of the nephritogenic epitope may influence
its ability to cause glomerulonephritis.
Goodpasture syndrome is an autoimmune disease
characterized by rapidly progressive glomerulonephritis,
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lung hemorrhage, and linear deposits of IgG along the
glomerular basement membrane (GBM) [1]. The disease
is mediated by autoantibodies to type IV collagen in the
GBM and lung alveoli [1]. The primary target for these
antibodies has been identified as the noncollagenous do-
main (NC1) of the a3 chain of col IV [a3(IV)NC1] [2–4].
The a3 chain, one of six genetically distinct a chains (a1
to a6) [4], is present only in certain specialized organ
basement membranes, including kidney and lung [5].
All of the a chains of collagen IV have similar struc-
tures: a short noncollagenous amino terminal domain, 7S;
a long central triple helical collagenous domain; and a car-
boxyl terminal NC1 domain [4]. The NC1 domains of all a
chains show high degrees of amino acid sequence homol-
ogy [6–8]. In addition, there is a highly conserved pattern
of 12 cysteine residues that form six intrachain disulfide
bonds in NC1. These disulfide bonds enable the NC1 do-
main to be properly folded into a three-dimensional glob-
ular structure [9]. Denaturation of NC1 by reducing the
disulfide bonds causes loss of reactivity to autoantibod-
ies, suggesting that the Goodpasture epitope is confor-
mational. This requirement for intact tertiary structure
for Goodpasture antibody binding is well recognized
[10, 11].
Over the past two decades, extensive efforts have fo-
cused on identifying the Goodpasture epitope. Work us-
ing linear synthetic peptides as well as using recombinant
proteins expressed in bacterial systems have been fraught
with problems and limitations in characterizing these
conformational epitopes [12–15]. Subsequent work from
several groups using recombinant a3(IV)NC1 expressed
in mammalian cells to preserve the three-dimensional
structure of the Goodpasture epitope have all demon-
strated the critical role of the amino terminal portion
of a3(IV)NC1 for Goodpasture epitope binding [16–
21]. Recent studies mapping the Goodpasture epitope
have used chimeric molecules of human a3(IV)NC1 and
a1(IV)NC1. With this approach, parts of the a3(IV)NC1
were replaced by the corresponding sequences of homol-
ogous but nonreactive a1(IV)NC1 [16, 19]. Using this
strategy, Hellmark, et al [16] and Borza et al [21] have
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further defined the amino terminal third of a3(IV)NC1
as the predominant binding site for Goodpasture an-
tibodies. Hellmark et al [16] showed that all of the
sera from 77 Goodpasture patients bind to this region,
and demonstrated correlation with progression of Good-
pasture disease [16]. Further mutational analyses have
demonstrated a limited number of critical amino acids in
the amino terminal end of a3(IV)NC1 relative to Good-
pasture sera binding [20–23].
Previous studies have been performed in vitro to
map antibody binding with various epitopes. None have
demonstrated that these epitopes not only bind Good-
pasture autoantibody, but also are capable of inducing
disease. The goal of the present study was to determine
whether the a3(IV)NC1 domain, particularly the amino
terminal portion of this domain (i.e., the antibody reactive
epitopes [16]) also contains epitopes causing nephritis. As
this cannot be studied in humans, we have utilized a model
of experimental autoimmune glomerulonephritis (EAG)
in rats. This model, induced by native or recombinant
GBM antigens, has been shown to result in severe pro-
liferative glomerulonephritis with crescents, hematuria,
proteinuria, and uremia; therefore, it mimics the organ-
specific form of human Goodpasture syndrome [24–26].
Similar models have been described in rabbits [27] and
mice [28, 29]. In this study, the potential capacity of differ-
ent portions of the a3(IV)NC1 domain to induce EAG
in rats was determined by using mammalian recombi-
nant a3(IV)NC1 and a3(IV)NC1/a1(IV)NC1 chimeric
proteins as immunogens. The results demonstrated that
the a3(IV)NC1 domain, and specifically the amino termi-
nal portion of a3(IV)NC1, induced EAG in rats. Further-
more, the presence of the middle portion together with
the amino terminal portion of a3NC1 enhanced EAG
production relative to other constructs. The results sug-
gest the conformational context of the nephritogenic epi-
tope influences its ability to cause EAG, and that specific
amino acids not only influence autoantibody binding, but
disease induction as well. Finally, adjacent nonnephrito-
genic regions of the construct seem to influence the de-
gree of EAG induced by the nephritogenic epitope.
METHODS
Experimental animals
Hypersusceptible normal male Wistar Kyoto (WKY)
rats, weighing 200 g, were purchased from Charles River
Laboratories (Wilmington, MA, USA). Animals were
maintained in standard conditions in the Department of
Comparative Medicine for several days of acclimatization
before experiments.
Antibodies
Human autoantibodies were from serum of patients
with Goodpasture syndrome. Monoclonal antibodies
specifically against the a3(IV)NC1 domain (Mab17)[30],
and against 6× histidine (6× his) epitope (anti-his.G)
(Qiagen, Valencia, CA, USA) were used. Rat sera
were from animals immunized with recombinant pro-
teins and native GBM. Horseradish peroxidase (HRP)-
conjugated antibodies and fluorescein isothiocyonate
(FITC)-conjugated goat antirat IgG and fibrinogen were
purchased from ICN/Cappel (Costa Mesa, CA, USA).
Preparation of bovine GBM
Bovine kidneys from a local abattoir were frozen at
−70◦C until used. Glomeruli were isolated from homog-
enized cortical tissue by differential sieving as previously
described [25, 31]. To prepare GBM for immunization,
whole glomeruli were sonicated on ice for 30 seconds
to obtain disrupted GBM. Portions of GBM were then
digested with type VII collagenase (Sigma Chemical
Co., St. Louis, MO, USA), and the resultant solubilized
GBM (csGBM) was lyophilized and used as immunizing
antigen.
Recombinant human a3(IV)NC1 and chimeric
a 3/a1(IV)NC1
The other immunizing antigens used in this study
were recombinant human a3(IV)NC1 and its chimeras
[16]. These included one full-length a3(IV)NC1 domain
(a3732) and three different a3 /a1 chimeric NC1 do-
mains. The strategy and method of constructing the a3/a1
chimeric proteins has been described previously in detail
[16]. Briefly, chimeric proteins were constructed by re-
placing thirds of the a3NC1 domain with the correspond-
ing sequence of the human a1(IV)NC1 domain using
polymerase chain reaction (PCR) methods. The different
chimeric proteins were obtained and named according
to the origin of the NC1 domain. The chimeric proteins
used in this study were as following: CP111 is the recom-
binant a1(IV)NC1 domain with four added restriction
sites (BamHI, HindII, XbaI, and NotI), which divided
a1(IV)NC1 into three regions (Fig. 1A); CP311 contains
one-third amino terminal portion of the a3(IV)NC1 with
the rest of the a1(IV)NC1 domain; CP331 consists of two-
thirds amino terminal portion of a3(IV)NC1 domain and
one-third carboxyl terminal portion of the a1(IV)NC1
domain. All of the chimeric cDNAs were inserted into
the expression vector, pCEP4-BM40-HisEK, which is
based on the pCEP4 vector (Invitrogen, Carlsbad, CA,
USA), and sequenced by ABI310 automated sequencer
(Perkin-Elmer, Boston, MA, USA). The constructs were
expressed in HEK-293 cells. The secreted proteins con-
tained a BM40 signal peptide followed by a 6× histidine
(6 his) tag and a 30 amino acid length of type X collagen
and the NC1 domain from collagen IV (Fig. 1A). All of
the constructs were tested for translation of protein with
the correct molecular weight (∼31 kD), using an in vitro
system (Promega, Madison, WI, USA) with S35-labeled
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Fig. 1. Schematic representation of cloning strategy for constructing human a3/a1 chimeric proteins [16, 23] and full-length human a3(IV)NC1
domain. (A) The chimeric constructs consist of a 6× His tag, a type X collagen triple helix (30 amino acids) and an a1 type IV collagen NC1
domain cloned into the mammalian expression vectors (pCEP4-BM40-HisEK). Three different chimeric constructs, CP111, CP311, CP331, named
according to the origin of the respective portions of the NC1 domain, are shown here. The BamHI, HindII, XbaI, and NotI cleavage sites were
introduced into the a1(IV)NC1 cDNA, and then homologous portions of the a3(IV)NC1 were exchanged. (B) Constructs EA and EB as described
in text. Amino acids of a3(IV)NC1 on the backbone of a1(IV)NC1 with antibody-immunodominant sites underlined [20, 21]. (C) The full-length
a3(IV)NC1 domain cloned into the expression vector (pSecTagA) was expressed as the fusion protein with a myc epitope and a 6× His tag at the
carboxyl terminus (a3732). The amino acid sequence for the a3(IV)NC1 of the chimeric constructs at the type X collagen/type IV collagen junction
is type X collagen/DPGLKG. The amino acid of a3732 at the amino terminus starts as SLGLKG. The signal peptides in (A) and (B) are cleaved off
in the cells.
cysteine and T7 RNA polymerase. HEK-293 cells used
for cDNA expression were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) with 10% fetal calf serum
(FCS) (Gibco BRL, Rockville, MD, USA) in the pres-
ence the selection reagent (G-418) Gibco BRL). Dur-
ing harvesting, the cells were kept in FCS-free DMEM/
F-12, and culture medium was collected and purified by
ProBind resin (Invitrogen).
Cultures of CP131 and CP113 did not produce suf-
ficient quantities of protein to allow isolation of the
construct and immunization of rats. Therefore, new con-
structs were developed to encompass both of the antibody
binding sites described by Hudson and Colleagues [20,
21]. To construct the two new chimeric proteins, we used
the extension PCR technique [22] (Fig. 1B). Construct
T195 EA (EA) consists entirely of a1(IV)NC1 domain
except for 45 amino acids of a3(IV)NC1. The Hudson
EA site is underlined. Likewise, T194 EB (EB) consists
entirely of a1(IV)NC1 with 37 amino acids of a3(IV)NC1
containing the Hudson EB site, underlined. Both con-
structs contain the BM40 signal peptide followed by a 6×
his tag + EK site and a short length of type X collagen as
described above.
a3732 is the full-length a3(IV)NC1 domain, without the
collagen X leader (Fig. 1C). The original cDNA encod-
ing the a3(IV)NC1 domain was a gift from A. Michael/M.
Kleppel. The 5′ end was extended by PCR amplification
to include the region coding the junction between the
triple helix and the NC1 domain (GLKGKRGDS. . .).
The construct was then subcloned into a mammalian ex-
pression vector (pSecTagA) (Invitrogen) and expressed
in the HEK-293 cell system. The secreted protein was
fused with a myc epitope and 6× his tag at the carboxyl
terminus. The cells were cultured and harvested as de-
scribed above except zeocin (Invitrogen) was used as
the selection reagent. The proteins from culture medium
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were purified by affinity chromatography using Ni-NTA
agarose columns (Qiagen). The protein was sequenced by
Edman degradation method and by mass spectrometry
[abstract; Bolton WK, et al, J Am Soc Nephrol 10:543A,
1999], and the expected size is ∼29 kD. All the recom-
binant proteins were quantified by bicinchoninic acid
(BCA) protein assay and by measuring the absorbance
at 280 nm.
Immunizations
The immunizing antigens were suspended in 0.1 mol/L
acetic acid and emulsified with an equal amount of com-
plete Freund’s adjuvant (CFA H37Ra) (Sigma Chemical
Co) and given as a single injection in the left hind footpad
and subcutaneously. Animals were divided into groups to
receive immunization with various recombinant proteins
and native GBM. The amount of protein injected into
each animal (100 lg/rat) was kept constant for all groups.
Group I rats were immunized with CP111 (N = 6), group
II rats with CP311 (N = 6), group III rats with CP331
(N = 6), group IV rats with a3732 (N = 6), group V rats
with bovine csGBM (N = 9), group VI rats with EA (N =
6), group VII with EB (N = 6), and group VIII with 50 lg
EA plus 50 lg EB (N = 5) (EA + EB). Control animals
(N = 3) received phosphate buffered saline (PBS) emul-
sified in an equal volume of CFA.
Urine analysis, serum creatinine, and urea nitrogen assays
Animals were placed in metabolic cages and 24-hour
urine samples were collected weekly following immuniza-
tion for a total of 7 weeks. Total urinary protein (TUP)
was determined using 3% sulfosalicylic acid with bovine
serum albumin (BSA) as a standard [25]. The upper limit
of normal for 24-hour TUP in rats is 10 mg. Urine was
also examined for hematuria (0 to 3+) using reagent
strips (Multistix 10 SG) (Bayer Corporation, Elkhart, IN,
USA). To measure serum creatinine and urea nitrogen,
blood samples obtained via the tail vein from each rat
every 2 weeks following immunization were examined
using diagnostic kits from Sigma Chemical Co. for creati-
nine (Procedure No. 555) and urea nitrogen (Procedure
No. 640).
Immunofluorescence studies and histologic examination
Kidney tissue was obtained at death from rats that
died of uremia, or at sacrifice, 8 to 12 weeks after
immunization. Tissue was snap-frozen in isopentane
(2-methylbutane) (Fisher, Newark, DE, USA) on dry ice.
For direct immunofluorescence staining of rat IgG and
fibrinogen, 4 lm cryostat sections of kidney were stained
with FITC-conjugated goat antirat IgG and fibrinogen.
The intensity of immune deposits was semiquantitatively
graded from 0 to 4+. For light microscopy, kidney tis-
sue was fixed in 10% buffered formalin, dehydrated in
alcohol, and embedded in paraffin. Sections were stained
with hematoxylin-eosin (H&E) and examined. Histologic
scores were assigned in a masked fashion, using a 4-point
scale [32].
Electrophoresis and immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) was performed in 12.5% gels,
under nonreducing conditions. For immunoblotting, the
proteins separated on SDS-PAGE were transferred to ni-
trocellulose membrane (Bio-Rad, Hercules, CA, USA).
The blotted membranes were blocked with 5% dry milk
in 0.1% PBS-Tween 20 and washed with PBS-Tween 20.
The membranes were then incubated for 2 hours with
primary antibodies diluted in PBS-Tween 20. Upon in-
cubation, the membranes were washed thoroughly with
PBS-Tween 20, followed by 1-hour incubation with HRP-
conjugated secondary antibodies. After washing four to
five times with PBS-Tween 20, the immunoreactive pro-
teins were identified using chemiluminescence (Pierce,
Rockford, IL, USA).
Enzyme-linked immunosorbent assay (ELISA)
Microtiter plates (Immulon II) (Dynatech, Chantilly,
VA, USA) were coated with 200 ng of antigen in 200 lL
of coating buffer. The plates were incubated overnight
at room temperature. After washing three to four times
with PBS-Tween 20, the plates were blocked with 1.5%
BSA/PBS-Tween 20 for 1 hour at 37◦C. The plates were
washed again with PBS-Tween 20 and incubated with
the various rat sera diluted in 1.5%BSA/PBS-Tween
20 for 2 hours at 37◦C. The plates were washed again
and incubated 1 hour at 37◦C with the HRP conjugated
secondary antibody (antirat IgG) at 1:5000 dilution in
PBS-Tween 20. The color was developed using the
ABTS substrate (2,2′azino-di-(3-ethylbenzthiozoline sul-
fonic acid)) (Sigma Chemical Co.). The absorbance for
each well was read at 405 nm using Multiscan ELISA
plate reader (MTX Lab Systems, Flow Laboratories,
McLean, VA, USA). All assays were run in duplicate.
Statistical analyses
Data are expressed as the mean ± SE. Statistical dif-
ferences between groups were evaluated by the Student
t test and analysis of variance (AVOVA) [31] using
the S-Plus program(Insightful Corporation, Seattle, WA,
USA). The presence or absence of the 6 his tag and
the collagen X leader protein, both different from na-
tive csGBM, could influence immune responses [33].
Therefore, comparisons of the first with the second part
of a3(IV)NC1 were made only for the nephritogenic
constructs containing the same structure (i.e., thirds of
a3(IV)NC1 and a1(IV)NC1, collagen X, and the 6 his
tag).
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RESULTS
Recombinant a3(IV)NC1 and chimeric
a3/a1(IV)NC1 domain
The immunizing antigens used in this study in-
cluded a full-length human recombinant a3(IV)NC1 do-
main (a3732), chimeric a3/a1(IV)NC1 constructs (CP111,
CP311, CP331, EA, and EB), as well as native bovine
GBM. All of the recombinant proteins were secreted into
the culture medium as the fusion proteins containing the
6× his tag [16], and purified by affinity chromatography
on Ni+ column. The proteins were quantified and exam-
ined by Western blot before injecting equal quantities
into animals. As shown in Figure 2, all the recombinant
proteins were recognized by the anti-histidine antibody
(anti-His.G), with CP111, CP311, CP331, EA, and EB at
the predicted molecular weight of approximately 31 kD,
and a3732 of 29 kD. Mab17, a monoclonal antibody spe-
cific for a3(IV)NC1, recognized a3732 as well as CP331,
which contains the two thirds amino terminal portion
of a3(IV)NC1 (Fig. 2A) [30]. Mab17 did not recognize
CP311, which contains the one third most proximal amino
terminal portion of a3(IV)NC1, nor EA or EB. The Mab
17 antibody epitope is known to be conformational and
requires both amino acids 17–31 (first third) and 127–141
(second third) of a3(IV)NC1 to bind [20]. Mab17 also
recognized native GBM, but not CP111, as expected. In
addition, serum from a patient with Goodpasture disease
(Fig. 2B and C) reacted with all the recombinant pro-
teins except CP111 and EB. Reactivity of the Goodpas-
ture serum with CP311, CP331 and a3732 was markedly
reduced or abrogated after reduction of the antigen
demonstrating reactivity with nonlinear, conformational
epitopes.
Reactivity of rat serum with recombinant
and native NC1 domain
Sera from animals were analyzed by ELISA for anti-
bodies against various constructs, as well as native NC1
domains from human, bovine, and rat GBM (Fig. 3).
The extent of response correlated well with the type of
construct used for immunization. Rats immunized with
CP111, an a1NC1 construct, showed a strong antibody
response against a3/a1(IV)NC1 chimeras with a higher
absorbance for CP311 than CP331, but no reactivity for
a3732. This reflects a greater number of B-cell epitopes
anti-His antibody and lanes 5 to 9 with Mab 17. The upper band in lane
9 is the native a3(IV)NC1 dimer. (B) Lanes 1 and 6 contain CP111,
lanes 2 and 7 contain CP311, lanes 3 and 8 contain CP331, and lanes 4
and 9 contain a3732. Lane 5 is empty. Lanes 1 to 4 were blotted under
nonreduced and lanes 6 to 9 under reduced conditions. (C) Lanes 1, 4,
and 7 contain EA, lanes 2, 5, and 8 contain EB, lanes 3 and 6 contain
csGBM. Lanes 1 to 3 were blotted with anti-His, lanes 4 to 6 with Mab 17,
and lanes 7 and 8 with Goodpasture serum. Blotted under nonreduced
conditions.
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Fig. 2. Immunoblotting of different constructs with anti-His antibody
(lanes 1 to 4), and Mab 17 (lanes 5 to 9), and with Goodpasture serum
from a patient under nonreduced and reduced conditions. Mab17 is spe-
cific for the conformational structure formed by approximation of sites
in the amino third of a3(IV)NC1 (amino acids 17–31) with the middle
third of a3(IV)NC1 (amino acids 127–141)[20]. (A) Lanes 1 and 5 con-
tain CP111, lanes 2 and 6 contain CP311, lanes 3 and 7 contain CP331,
lanes 4 and 8 contain a3732, and lane 9 contains native glomerular
basement membrane (GBM) (bovine). Lanes 1 to 4 were blotted with
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Fig. 3. The specific reactivity of sera from construct-immunized rats
toward various recombinant proteins and native NC1 domain was de-
termined by direct enzyme-linked immunosorbent assay (ELISA). Sera
from the 6-week bleed were used at 1:500 dilution. The serum anti-
bodies bind specifically to the recombinant as well as the native NC1
domains purified from bovine (bNC1), rat (rNC1), and human (hNC1)
glomerular basement membrane (GBM). NC1 domains were prepared
by multistage column chromatography, as described previously in de-
tail [61, 62]. Chimeric construct-immunized rats developed antibody to
type X collagen (col X), but not those immunized with a3732. Mean ±
SEM.
for anti a1NC1 antibodies on CP311 than on CP331, and
even less on a3732. It also reflects the antibodies to col-
lagen X on chimeric proteins, not present on a3732. By
contrast, rats immunized with a3732, an a3NC1 construct,
showed a similar but reversed antibody response, with
highest response against CP331, moderate against CP311
and minimal against CP111. Animals immunized with
a3/a1(IV)NC1 chimeras (CP311 and CP331) showed an-
tibody responses to a3732, a3 chimeric proteins, and a1
chimeric proteins to a similar extent. Thus, each recom-
binant antigen elicited the greatest antibody response to
itself, as expected. The response to other constructs re-
flected the composition of the construct and plate antigen.
Animals immunized with larger segments of a1 con-
structs had higher reactivity vs. constructs with greater
percent a1 in the construct, and an inverse reactivity
with a3732. In addition, all animals demonstrated a robust
response to native NC1 domains from human, bovine,
and rat GBM which contain both a3NC1 and a1NC1. The
greater amount of antibody binding in sera from CP111
and CP311 immunized rats for human NC1 could be due
to the higher composition of a1(IV)NC1 in the prepa-
ration. All rats immunized with chimeric proteins, which
contain collagen X, developed a strong antibody response
against collagen X. Rats immunized with a3732, lacking
collegen X, showed no reactivity. Finally, sera from rats
immunized with constructs containing EA and EB, con-
sisting mostly of a1 chain plus collagen X and histidine,
had broad spectrum reactivity to antigens containing
either a1 or a3 moieties, as would be expected. Negative-
control rats immunized with CFA alone did not exhibit
any antibody response against any recombinant or native
protein (data not shown).
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Fig. 4. Time course of proteinuria of rats immunized with different
constructs and native glomerular basement membrane (GBM). Total
urine protein (TUP) of each animal in each immunization group was
determined weekly. Results shown represent the mean TUP of each
group. Normal TUP < 10 mg. The degree of proteinuria for CP111 and
EB were not different from complete Freund’s adjuvant (CFA) rats. All
other constructs resulted in proteinuria significantly greater than CFA,
CP111, and EB, P < 0.05. TUP was not different between csGBM and
CP331 rats. TUP for csGBM rats was significantly greater than all other
proteinuric groups (P < 0.05 to P < 0.0004). CP331 induced greater
proteinuria than a3732 (P < 0.02).
Nephritogenicity
Proteinuria. As shown in Figure 4, animals immunized
with CP311, CP331, a3732, and native GBM all developed
proteinuria beginning 3 to 4 weeks following immuniza-
tion, which increased with time throughout the course of
the study. However, there were differences in the time
of onset and severity of proteinuria among the different
construct recipient rats, despite the presence of antibody
with similar binding against native bovine and rat GBM.
CP331 was the most potent chimeric protein construct
for inducing rat EAG. All six rats receiving CP331 had
heavy proteinuria at 4 weeks following injection, reach-
ing a mean level of 73 ± 36 mg/24 hours at 5 weeks, similar
to protein excretion levels of rats given native GBM. By
contrast, only two of six rats given CP311 and one rat
given a3732 had proteinuria at 4 weeks. The development
of proteinuria among CP331 recipient rats was so rapid
and severe, that by the time of sacrifice (8 weeks), only
two of six CP331 rats survived, the others dying of ure-
mia. A slower and less pronounced degree of proteinuria
was seen in animals immunized with CP311 and a3732. At
7 weeks following injection, five of six rats given CP311
and four of six rats given a3732 developed proteinuria.
Rats immunized with EA developed heavy proteinuria
with the same time course and severity of CP311, while
only one of six EB immunized rats had mild proteinuria.
EA and EB rats immunized with half-dose antigen, none-
the-less had proteinuria comparable to CP311 and EA
full-dose rats. Among six rats given CP111, only one rat
had mild proteinuria (24 mg/24 hours), which started at
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in each immunization group at week 5 following injection. aP < 0.05
vs. csGBM. Complete Freund’s adjuvant (CFA) rats did not develop
hematuria.
week 5 and continued at the same level throughout the
rest of study. Negative-control animals given CFA alone
did not develop any abnormal proteinuria. Differences in
protein excretion with time (Fig. 4) reflect a combination
of factors in this model including a peak of proteinuria
at weeks 4 to 6, death of the most proteinuric rats, and
diminished proteinuria with time as we and others have
observed [26].
Hematuria. The urines of all animals were tested for
hematuria. The results (Fig. 5) correlated well with the oc-
currence of proteinuria. At 5 weeks following injection,
while one CP331-immunized rat had died of uremia, all
CP331 rats except one had heavy hematuria, similar to
rats immunized with native GBM. Only two CP311 and
two a3732 recipient rats had heavy hematuria at 5 weeks.
By 7 weeks, all CP331 recipient rats had severe hematuria,
as did five CP311 recipient rats and four a3732 recipient
rats. Hematuria in EA and EA + EB rats was compara-
ble to other nephritic rats. Two EB-immunized rats had
hematuria and a third EB rat had trace hematuria. Rats
immunized with CP111, however, showed minimal hema-
turia throughout the course of study. One animal had
light hematuria without deposits by fluorescence and no
glomerulonephritis by light microscopy. One rat had trace
fluorescent deposits of IgG and fibrin and mild protein-
uria and glomerulonephritis.
Serum urea nitrogen and creatinine. The serum urea
nitrogen and creatinine were also determined in animals
injected with various recombinant proteins (Fig. 6). Rats
given CP 331 showed a progressive increase in serum
urea nitrogen beginning by 4 weeks following immuniza-
tion which increased to 235 mg/dL at the time of sacri-
fice (8 weeks). CP311, CP111, and a3732 recipient rats did
not develop significant elevations in serum urea nitrogen.
CP331 immunized rats also had an increase in the serum
creatinine from 0.5 mg/dL to 2.6 mg/dL, while no signif-
350
300
250
200
150
100
50 
0
Se
ru
m
 B
UN
, m
g/
dL
CF
A
cs
GB
M
CP
111
CP
311
CP
33
1
α3 7
32 EA EB
EA
+E
B
Immunization group
CF
A
cs
GB
M
CP
111
CP
311
CP
33
1
α3 7
32 EA EB
EA
+E
B
Immunization group
Week4
Week6
Week8
Week4
Week6
Week8
4.0
3.0
2.0
1.0
0.0Se
ru
m
 c
re
at
in
in
e,
 m
g/
dL
b
a 
a
b
a
a
a
A
B
Fig. 6. Levels of serum urea nitrogen (A) and creatinine (B) in rats
immunized with various recombinant proteins and native glomerular
basement membrane (GBM). aP < 0.05 vs. complete Freund’s adjuvant
(CFA) controls; bP < 0.05 vs. CP331.
icant abnormality was observed in CP311, CP111, and
a3732-immunized rats. EA and EA + EB immunized rats
had increases in creatinine compared to CFA and CP111
rats. EB rats had no increase in blood urea nitrogen or
creatinine. Consistent with our previous findings [25], rats
immunized with native bovine csGBM showed a mild in-
crease of serum creatinine from 0.6 mg/dL to 1.1 mg/
dL at time of sacrifice, although no significant change for
serum urea nitrogen levels was observed. With additional
time, csGBM immunized rats routinely develop elevated
blood urea nitrogen and creatinine, and die of kidney
failure.
Histologic findings
Direct immunofluorescence for IgG and fibrinogen.
Rat IgG was deposited in a linear pattern along the GBM
and to a lesser extent along the tubular basement mem-
brane (TBM) in all rats except those immunized with
CP111 (Fig. 7). However, the intensity of IgG staining
on the GBM in animals immunized with recombinant
proteins was significantly less than that seen in animals
immunized with native GBM, despite the presence of in-
tense fibrinogen deposition.
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Fig. 7. Histologic scoring by immunofluorescence in rats immunized
with recombinant proteins and native glomerular basement membrane
(GBM). Kidney sections were stained for rat IgG and fibrinogen. Mean
± SEM. aP < 0.0005 vs. csGBM; bP < 0.001 vs. CSGBM; cP < 0.01 vs.
csGBM; dP < 0.02 vs. csGBM; eP < 0.005 vs. CP331.
CP331 immunized rats had intense fibrinogen deposits
within the glomeruli in a pattern and distribution com-
parable to that seen in animals immunized with native
GBM (Fig. 7). CP311- and a3732-immunized rats showed
less intensity of fibrinogen deposits compared to CP331
recipient rats. EA-immunized rats had IgG and fibrino-
gen deposits comparable to csGBM, while only one EB-
immunized rat had trace to one plus deposits of IgG and
fibrinogen. EA + EB-immunized rats had minimal IgG
deposits, but fibrinogen comparable to csGBM.
Among six CP111-immunized rats, only one rat with
mild proteinuria and hematuria showed trace linear IgG
staining along the GBM with minimal fibrinogen deposits.
The other five rats showed neither IgG binding nor de-
posits of fibrinogen within glomeruli. Negative-control
animals given CFA alone showed no antibody binding
(data not shown).
Light microscopy. Analysis of histologic damage
by light microscopy (Fig. 8) revealed severe glomeru-
lonephritis in CP331 immunized rats, comparable to that
seen in native GBM immunized rats and described in de-
tail previously [25, 32]. Examples of histology are pro-
vided in Figure 9. The degree of damage in two rats
reached the highest score 4, and the remaining four rats
showed scores of 3 to 3.5. This was associated with intense
interstitial fibrosis and tubular atrophy, and interstitial
mononuclear cell infiltrates. Modest glomerular abnor-
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Fig. 8. Histologic scores by hematoxylin and eosin for rats immunized
with various constructs. aP < 0.001 vs. csGBM; bP < 0.03 vs. csGBM;
cP < 0.01 vs. CP331; dP < 0.02 vs. CP331.
malities were seen in half of CP311- and a3732-immunized
rats (range of score 2 to 3). Five of six EA-immunized
rats had glomerulonephritis comparable or worse than
csGBM and comparable to CP331. EA + EB rats had
severe glomerulonephritis similar to csGBM. One of six
EB rats had very mild glomerulonephritis. The CP111-
recipient animals had normal glomeruli except the one
with hematuria and proteinuria, which had focal areas
of interstitial fibrosis. Animals given CFA alone showed
completely normal glomeruli.
DISCUSSION
Goodpasture syndrome consists of glomerulonephri-
tis with pulmonary hemorrhage associated with circulat-
ing and tissue-bound antibodies to basement membranes.
Studies in animals immunized with GBM have demon-
strated the disease can be transferred by antibody alone
[28, 34, 35]. However, the disease is T-cell dependent for
its induction and can be transferred by sensitized T cells
[28, 31, 36–40]. Animals immunized with GBM develop
a broad spectrum of antibodies to various NC1 domains.
Serum from patients with Goodpasture syndrome also
have a broad spectrum of antibodies against various com-
ponents of the GBM with most directed to collagen IV
[14, 41–43]. However, the majority of antibody reactivity
is to a3(IV)NC1 domain [41, 42]. Further evidence for the
role of a3NC1 in disease production has been provided by
the production of glomerulonephritis in animals immu-
nized with monomers and dimers of a3 and recombinant
a3(IV)NC1 [27, 44, 45]. While the immunodominance
demonstrated by Goodpasture syndrome sera binding to
the amino terminal portion of a3 would suggest that this
region contains the epitope responsible for induction of
the disease [16, 18–23], some investigators have demon-
strated immunoreactive regions in other portions of a3,
including amino acids 127–141 and the carboxy terminal
36 amino acid [18, 20, 21]. The presence of circulating
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Fig. 9. Illustrative examples of histologic grading scores from animals immunized with recombinant proteins. (A) Section from an animal immunized
with CP111 showing normal glomerular architecture, absence of tubular abnormalities, identical to normal rats (hematoxylin and eosin ×4000. (B)
Section from an animal immunized with EB, the only animal of this group to show histologic abnormalities, illustrating a 1+ lesion with segmental
tuftal proliferation but no other abnormalities (hematoxylin and eosin ×400). (C) Animal immunized with recombinant protein m732 illustrating a
2+ lesion in a glomerulus with hypercellularity decreased capillary lumens (hematoxylin and eosin ×400). (D) CP331 immunized animal showing
3+ glomerular proliferation with tubular dilatation, marked decrease in capillary lumens and Bowman’s space, and early interstitial infiltration
(hematoxylin and eosin ×400). (E) Section from a rat immunized with EA illustrating a 4+ lesion with marked glomerular compression with a
fibrocellular crescent, and tubular dilatation with casts (hematoxylin and eosin ×400). (F) Low power view of an animal immunized with CP331
illustrating 4+ lesions with glomerular obsolescence, glomerular fibrosis and crescents, tubular dilatation with marked cast formation, and interstitial
cellular infiltration (hematoxylin and eosin ×200). Detailed histologic descriptions on a chronologic basis and grading are provided in [25, 32].
antibodies may not portend pathogenic consequences as
demonstrated in multiple animal models of autoimmune
organ-specific disease transferable by activated T cells
[39, 46–50]. In addition, epitope spreading whereby the
initiating pathogenic epitope can result in the recruitment
of additional epitope-specific T and B cells may result in
antibodies and T-cell proliferation as an epiphenomenon
of the process. This may or may not contribute to tissue
damage [51, 52]. This suggests caution in extrapolating
data from in vitro antibody binding studies to pathogenic
events occurring in vivo. Since it has previously been
shown that the nephritogenic epitope in the experimen-
tal analogue of Goodpasture syndrome, EAG in rats, re-
sides in a3(IV)NC1, we have investigated whether the
in vitro antibody binding information from Goodpasture
syndrome sera and NC1 domains correlates with disease
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induction in this model. Identification of both the target
epitopes involved in initiation of EAG and the epitopes
responsible for induction of disease is important to better
understand the pathogenesis of the process and provide a
framework for the development of therapeutic strategies
in humans.
The construction of chimeric proteins allows examina-
tion of the role of site-specific conformational epitopes
in the experimental model, which are not available us-
ing synthetic polypeptides. Indeed, studies by a number
of investigators suggest that conformational epitopes re-
quiring interaction of amino acids at great lengths from
each other in the a3(IV)NC1 domain are necessary for
antibody binding and presumably for disease induction
[20–23]. However, in vitro antibody binding does not pro-
vide proof of the ability of epitopes to induce disease.
For these reasons, we are investigating epitopes that may
be involved in disease induction to determine if these
are the same epitopes recognized by antibodies from
patients with Goodpasture disease and to identify the
specific epitope or epitopes involved in the pathogenesis
of EAG.
The chimeric proteins used in the current study have
been shown to bind the serum of patients with Goodpas-
ture syndrome [16, 22]. The constructs were designed to
consist of thirds of the a3(IV)NC1 domain with various
thirds of a1(IV)NC1 domain. Whole-chain a3(IV)NC1
has been shown to bind Goodpasture syndrome and to
induce EAG, while a1(IV)NC1 does not cause EAG nor
bind Goodpasture syndrome serum [16, 45, 53]. We have
previously shown that constructs containing the amino
terminal third of a3 had the highest level of binding
and worse prognosis than for patients demonstrating
other antibody activities [16]. The results of the cur-
rent experiments also demonstrated the necessity for the
amino terminal portion of a3 for induction of disease
in animals. Rats immunized with the chimeric back-
bone of a1(IV)NC1 domain had no glomerulonephritis
while those immunized with whole a3(IV)NC1 domain or
chimeric protein constructs consisting of the first third or
the first plus second third of a3 developed EAG. We had
hypothesized that the amino terminal third would con-
tain the nephritogenic epitope based on antibody-binding
studies in vitro. Indeed, CP311 did induce EAG. How-
ever, the disease was less florid with less proteinuria and
slower onset than that seen with CP331 or native GBM
despite identical amounts of antigen and conditions of
immunization. The degree of intramolecular interaction
of the immunogen in our studies is unknown, as the anti-
gen is emulsified in CFA and then injected. Most of the
chimeric protein constructs appeared to be monomeric,
as opposed to csGBM (Fig. 2) and monomers induce less
disease than dimers [44]. However, the amount of native
a3(IV)NC1 monomer/dimer in csGBM, 3% [54] is far less
than in the recombinant proteins, implying much greater
propensity of native antigen to induce disease. CP331,
flanked by the collagen X leader protein and the mid-
dle portion of a3(IV)NC1, induced a more florid disease
than CP311 or a3732 and was comparable to that induced
by native csGBM (Figs. 4 and 6 to 8). Since CP311 would
only contain the first of two epitopes described by Netzer
et al [20] and Borza et al [21] and CP331 would contain the
first and second epitope described by that group, it might
be postulated that the two epitopes together are neces-
sary for full-disease expression. However, a3732 contain-
ing the entire a3(IV)NC1 domain but lacking the collagen
X leader protein actually produced slightly less severe dis-
ease and was slower in onset than either CP311 or CP331.
This could be consequent to the factors noted above. It
could also suggest that the collagen X leader protein may
have had some role in the severity of disease production
after immunization or that the folding of the molecule
is differently affected by collagen X or the neighboring
construct. Studies with EA and EB constructs confirmed
the pivotal importance of the amino terminal third of
a3(IV)NC1 for disease induction. EA induced florid dis-
ease, similar to full-length native csGBM and constructs
containing the full amino terminal third of a3(IV)NC1.
EB alone, containing the second antibody immunodomi-
nant region, induced essentially no disease. Yet half dose
of EA + EB induced full-spectrum disease. The degree
of severity of glomerulonephritis in this model is dose
related (personal observation [24, 55, 56]). Thus, compa-
rable disease of half-dose EA plus half-dose EB further
suggests an augmenting effect of the second third of the
molecule on disease induction, even though the EA and
EB sites were on different chains. Future studies will need
to address a possible augmenting role of the collagen X
leader protein.
The antibodies that developed after immunization with
the various constructs are consistent with a robust re-
sponse to the collagen X leader protein in CP311, CP331,
CP111, EA, and EB-immunized animals. Since we did
not have chimeric proteins of these constructs lacking the
collagen X leader protein, we were unable to distinguish
the antibody specificities for the collagen X compared to
the remainder of the chimeric protein. Rats immunized
with a3732 did not respond to collagen X or CP111, and
animals immunized with chimeric protein containing the
amino third or amino two thirds of a3 responded to a3372
lacking collagen X, while CP111 did not. These findings
are consistent with a species of a3372, CP311, and CP331
antibodies specific for the a3(IV)NC1 domain, without
significant anti-a1NC1 cross-reactivity, as shown by Sado
et al [45]. As demonstrated here, and by other studies,
immunization with a1NC1 induces circulating antibody
to a1NC1, but not deposition on the GBM, despite its
high content of a1(NC1) [4, 45, 53, 54, 57–59].
The histologic findings in the present study are of inter-
est. Native csGBM antigen immunization was associated
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with intense deposits of IgG on the GBM and formation
of crescents with a marked interstitial infiltrate, fibrosis,
and scarring as previously described [25]. Much lesser
amounts of GBM-bound IgG were noted with CP311,
CP331, and a3732. While this might be presumed to be
on the basis of their monomeric conformation, since
NC1 monomers induce less disease than dimers [44],
the histologic and clinical consequences of immunization
with these constructs suggest that other factors may also
be involved. As shown in Figures 4 to 8, despite their
monomeric conformation, there was considerable differ-
ence in the ability of these three constructs to induce
EAG. This suggests that factors other than failure to as-
sume a dimeric conformation were involved in the vari-
ance in disease induction.
The differences in the amount of GBM-bound IgG may
result from several possibilities. It is known from both
humans and experimental animals that anti-GBM anti-
bodies can be formed, deposited on the GBM, be clearly
detectable by immunofluorescence, and yet cause no dis-
ease [25, 56, 60]. Presumably the epitope specificities for
the antibody are important in disease induction. This is
suggested by studies transferring disease with antibodies
derived from urine, serum, and monoclonal antibodies
that induce florid glomerulonephritis after fixation to the
GBM [28, 34, 35]. It is also possible that epitope spread-
ing occurs with release of GBM antigens and the forma-
tion of secondary antibodies, which then deposit in the
GBM, increasing the overall amount of IgG present in the
GBM seen in csGBM-immunized rats [51, 52]. This, how-
ever, seems unlikely since rats immunized with CP331 had
disease comparable to that seen in csGBM animals but
markedly less GBM-bound IgG. On the other hand, since
it is known that EAG is T-cell dependent [28, 31, 36–40],
one could postulate that there are several or multiple
T-cell epitopes that may be responsible for the overall
phenotypic expression of the disease either alone or in
combination with antibody, and that the repertoire of
T cells activated by the various constructs influence the
phenotypic expression. Evidence to support this is indi-
rectly suggested by the studies in which two discrete sites
of a3(IV)NC1 domain, amino acids 17–31 and 127–141,
appear to be involved in in vitro studies of binding to
Goodpasture sera [20, 21]. The first site, amino acids 17–
31, would be contained in our chimeric protein constructs
CP311 and EA, whereas both sites would be contained in
CP331. It is further supported by the description of multi-
ple T-cell epitopes in this model and humans [32]. In addi-
tion, the type of epitope-initiated disease may play a role
in the degree to which recruitment of nonspecific T cells
and macrophages may occur, with subsequent augmen-
tation of injury. Further evidence of a potential T-cell–
dependent antibody independent mechanism is provided
by studies of Wu et al [33, 39]. They immunized rats with
linear recombinant bacterial a3(NC1), which induced
EAG without GBM-bound antibody but with circulating
antibody to immunogen and EAG transfer with cells.
Multiple antibody binding sites of a3(IV)NC1 have
been identified by various investigators [32], with two
immunodominant antibody binding sites [16, 20–22]. Our
studies confirm our postulate that the immunodominant
antibody binding sites on a3NC1 domain are also capable
of inducing EAG in our model. However, only the amino
terminal site containing Hudson EA, induces glomeru-
lonephritis, not the second, EB site. Our studies also sug-
gest that other portions of the molecule than the amino
terminal third may be involved in disease induction or
modification of disease expression. It raises the possi-
bility that more than one epitope may be involved and
that flanking regions related to the nephritogenic epitope
influence disease expression. Additional studies will be
necessary to further clarify these possibilities and to fur-
ther define the nephritogenic epitopes involved in EAG
production. Refinement in the delineation of the nephri-
togenic epitopes provides an infrastructure whereby
peptide specific immunotherapy directed to T-cell epi-
topes could eventually become part of the therapeutic
armamentarium for treatment of patients with Goodpas-
ture disease. The current studies narrow the spectrum of
potential disease responsible epitopes and provide yet
further support for the concordance of the experimental
animal model to the analogous disease in humans.
NOTE ADDED IN PROOF
After we reported the observations that are the basis
for the current manuscript [abstract; Bolton WK, et al, J
Am Soc Nephrol 11:472A, 2000], Borza et al reported in
abstract form confirmation that the EA amino terminal
portion of a3(IV)NC1 induced disease while the second
portion, EB did not, and that the EA + EB combination
produced more severe disease [abstract; Borza D-B, et
al, J Am Soc Nephrol 13:171A, 2002]. They also reported
that other segments a3(IV)NC1 did not induce disease,
but did not report antibody responses nor possible mod-
ulating effects of other portions of the molecule.
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